 |
| Ebolavirus under an electron microscope--Courtesy of CDC |
Tekmira ($TKMR), developer of an RNAi treatment for Ebola, has come to terms with regulators on an access program for its in-development drug, allowing the company to provide doses to patients who have contracted the deadly virus. Through agreements with the FDA and Health Canada, Tekmira said it has established a framework for supplying and administering its lead drug, TKM-Ebola. As CEO Mark Murray points out, the expanded access program for TKM-Ebola doesn't constitute a controlled clinical trial, but the infused treatment has been well-tolerated so far. Tekmira is studying the drug under a partial FDA clinical hold after the agency took issue with some safety signals. More